

Scientific Letter

Identification of Genetic Factors Associated With DAMP Release in COPD Patients

To the Director,

Over the past decade it has become increasingly evident that endogenous danger signals, called damage associated molecular patterns (DAMPs), released from damaged or dying lung resident cells play a pivotal role in the pathophysiology of chronic obstructive pulmonary disease (COPD).^{1,2} It has been consistently shown that the levels of DAMPs are increased in the lungs of COPD patients compared to non-COPD controls, in bronchoalveolar lavage fluid, epithelial lining fluid or sputum,^{3–5} as well as systemically in serum or plasma.^{6–8} These increased DAMP levels originate from structural and immune cells that are exposed to damaging agents upon inhalation of toxic gases and particles, like cigarette smoke, exhaust fumes or air pollution.^{9,10} Previously, we showed that the amount and type of DAMPs that are released upon inhalation of cigarette smoke, has a strong genetic component.^{11–13} However, to date it is still unknown which genetic factors increase the susceptibility for DAMP release. This study aimed to increase our understanding of the factors involved in susceptibility to DAMP release, which are potentially contributing to the susceptibility to develop COPD. This is the first study assessing the association between genetic factors and the levels of DAMPs in serum.

To this end, data was collected from 165 severe COPD (GOLD stage 3–4) patients of the Groningen Severe COPD cohort (NCT04023409), who were all ex-smokers with >5 pack-years of smoking history but have not smoked for >6 months prior to sampling. Forty-nine of the subjects were male with a mean age of 55 years (between 36 and 77), an average number of pack-years of 36.7 (SD = 15.0), average lung function of 28 (SD = 6.7; FEV1/FVC%), and a mean emphysema score of 40.2% (SD = 7.5; %voxels <950 Hounsfield Units upon expiration). The study was approved by the medical ethical committee of the University Medical Center Groningen, and all participants provided written informed consent.

A panel of 4 DAMPs (α -Defensin, Galectin-9, sRAGE, dsDNA) was measured in serum of 165 COPD patients. The levels of α -Defensin (Human alpha-Defensin 1 DuoSet ELISA, DY8198-05, R&D Systems, Minneapolis, MN), Galectin-9 (Human Galectin-9 DuoSet ELISA, DY2045, R&D Systems) and the soluble Receptor for Advanced Glycation End-products (sRAGE; Human RAGE DuoSet ELISA, DY1145, R&D Systems) were measured by ELISA according to the manufacturer's protocols. The levels of double-stranded (ds)DNA were measured using Quant-iT™ PicoGreen™ dsDNA Assay Kits (P7589, Invitrogen, Waltham, MS). Whole-exome sequencing was performed on blood DNA using the Illumina platform and subsequently mapping the sequence to the Human Genome build 38. Full-

genome gene expression data was obtained from bronchial brushes from 123 of the donors. The number of rare variants within a gene was assessed with the burden test using the sequence kernel association test (SKAT) method.¹⁴ *p*-Values were computed using the SKAT.Null.Model function, in which each DAMP was defined as a continuous trait, and correction for age and smoking history was applied. Multiple testing correction was performed using the Bonferroni correction.

To test whether the levels of DAMPs in serum associated with the amount of potentially damaging rare variants of a gene, a genome-wide burden test was performed. This test assessed the associations between all variants within a gene and the serum levels of DAMPs. Manhattan plots indicate the different genes and their genomic location that were found to be significantly associated with the levels of dsDNA, Galectin-9, sRAGE and α -Defensin in serum (Fig. 1A–D). Nine genes were identified containing significantly more rare variants in COPD patients with high serum levels of dsDNA (*HHLA2*, *ORM1*, *MROH6*, *SYT7*, *GJB4*, *HEATR6*, *OR2V2*, *TF*, *PLEK2*). Eleven genes contained significantly more rare variants in COPD patients with high serum levels of Galectin-9 (*TRAPPC2L*, *LYZ*, *C8B*, *RGS9*, *SOAT2*, *ZBTB32*, *PDE11A*, *OR5H6*, *HAPLN3*, *IGLV5-45*, *ANKRD22*), while two genes contained more rare variants in COPD patients with high levels of sRAGE (*FAM175A*, *AARS2*). No genes were associated with the serum levels of α -Defensin. No obvious molecular pathways or biological functions were found to be related to the identified genes upon performing gene ontology enrichment analysis (The STRING database, <http://string-db.org>).

Next, the associations between serum levels of DAMPs and single nucleotide polymorphisms (SNPs) were assessed, using a protein quantitative trait locus (pQTL) analysis. Rare variants with a minor allele frequency of <4% were excluded. Table 1 shows the five SNPs that were identified to be significantly associated with the serum levels of DAMPs. Two of the SNPs were in full linkage disequilibrium (LD). The SNPs were located within the coding region of four different genes. No overlap between the identified pQTLs and genes containing more rare variants was found.

Next, to test whether the identified SNPs affected the expression of the associated genes, broncho-epithelial gene expression of the four identified genes, *i.e.* *SLC4A4*, *VAV1*, *KIF18A* and *SEMA6C*, were correlated with the levels of the associated DAMPs in serum. No correlation was found between serum dsDNA levels and *SLC4A4* and *VAV1* or between serum sRAGE and *SEMA6C*. However, a small but borderline significant correlation was found between the serum levels of Galectin-9 and bronchial gene expression of *KIF18A* (Fig. 1E).

This is the first study investigating the genetic factors involved in susceptibility to DAMP release. We identified five SNPs, located within the coding region of four genes that are associated with the

<https://doi.org/10.1016/j.arbres.2024.06.020>

0300-2896/© 2024 The Author(s). Published by Elsevier España, S.L.U. on behalf of SEPAR. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

Please cite this article as: F.S. Boedijono, V. Bood, I.A. Eichhorn et al., Identification of Genetic Factors Associated With DAMP Release in COPD Patients, Archivos de Bronconeumología, <https://doi.org/10.1016/j.arbres.2024.06.020>




Fig. 1. Association between serum DAMP levels and the number of rare variants within a gene. A genome-wide burden test was performed to test the association between the serum levels of (A) dsDNA, (B) Galectin-9, (C) sRAGE, and (D) α-Defensin and the number of variants within a specific gene. The genomic location, and corresponding chromosomes are shown on the x-axis and the log transformed p -values are shown on the y-axis, a corrected p -value higher than $-\log_{10}(p)$ was considered statistically significant (presented as a horizontal line). (E) Association between the serum levels of Galectin-9 and broncho-epithelial gene expression of KIF18A. Pearson correlation coefficient (r) and associated p -value are shown.

Table 1
Significant Associations Between the Serum Levels of DAMPs and SNPs.

| SNP | DAMP | Beta | p -Value | FDR | MAF % | Variant Type | Gene | Gene Name |
|------------------------|-------|--------|------------|--------|-------|--------------------|--------|--|
| rs1453458 | dsDNA | -100.8 | 1.93E-08 | 0.001 | 0.054 | Synonymous variant | SLC4A4 | Solute carrier family 4 member 4 |
| rs149865022/rs76873911 | dsDNA | 110.1 | 1.24E-06 | 0.0215 | 0.042 | Intron variant | VAV1 | Vav guanine nucleotide exchange factor 1 |
| rs12272419 | Gal-9 | 1156.3 | 9.78E-08 | 0.0051 | 0.042 | Missense variant | KIF18A | Kinesin family member 18A |
| rs74949844 | sRAGE | 321.3 | 2.80E-07 | 0.0146 | 0.061 | Synonymous variant | SEMA6C | Semaphorin 6C |

p -Values represent the nominal p -value. A genome-wide false discovery rate (FDR) of <0.05 was considered genome-wide significant. Rs149865022 and rs76873911 are in full linkage disequilibrium.

levels of DAMPs in serum of COPD patients. Out of these SNPs, only rs12272419 within the *KIF18A* gene is a missense variant leading to an amino acid change, potentially explaining why only the bronchial gene expression of *KIF18A* correlated with serum DAMP levels. *KIF18A*, a member of the kinesin superfamily, is involved in cell proliferation and mitosis, by regulating the dynamics of microtubule-associated molecular motors. Over-expression of *KIF18A* promotes cell proliferation and inhibits apoptosis.¹⁵ It is possible that in COPD, a disease where cell death processes like apoptosis, necroptosis and efferocytosis are dysregulated,^{16,17} further dysregulation of the cell death and proliferation mechanisms contribute to additional DAMP release. Likewise, sodium bicarbonate cotransporter 1 (SLC4A4), is also involved in the regulation of cell death, as it is involved in necroptosis, a regulated form of necrosis.¹⁸ Necroptosis has been shown to be one of the main contributors of DAMP release upon inhalation of cigarette smoke,¹⁹ and is increased in experimental and human COPD models.¹⁷

The amount of rare variants of specific genes was found to be associated with the levels of DAMPs in serum of COPD patients. No specific pathway or relationship between the identified genes was observed. Future studies should be focused on identifying the exact role of the increased number of rare variants within these genes and the levels of DAMPs in serum. It is likely that the increased number of mutations of these genes contribute to the release of DAMPs in the lungs upon cell damage, yet it is also possible that high levels of DAMPs in serum increases the mutation frequency of specific genes. The panel of DAMPs was selected to comprise a range of DAMPs originating from different subcellular compartments and that can activate different pattern recognition receptors. However, it is possible that a different selection of DAMPs would have led to the identification of different DAMPs.

Although we aimed to identify general susceptibility genes for DAMP release, we chose to use a cohort consisting exclusively out of COPD patients, since these patients have higher systemic levels of DAMPs. To this end, we cannot exclude the possibility that the identified susceptibility genes are related to DAMP release only in COPD patients. Future studies should be aimed at validating whether the DAMP release-related genes identified in this study are also involved in DAMP release in non-COPD patients.

In conclusion, this study confirmed that the susceptibility to the release of DAMPs has a strong genetic component. Several SNPs and susceptibility genes were identified that are associated with the release of DAMPs in COPD patients.

Ethical Approval

The study was approved by the medical ethical committee of the University Medical Center Groningen, and all subjects provided written informed consent. Severe COPD patients are derived from ClinicalTrials.gov Identifier: NCT04023409. Data from these study cohorts can be accessed through collaboration by contacting Maarten van den Berge (m.van.den.berge@umcg.nl).

Funding

Simon D. Pouwels was funded by a Dutch Research Council (NWO) VENI grant (no. 09150162010003).

Authors' Contributions

Concept & design: AF, SDP. Data analysis: FSB, AF, SDP. Patient inclusion/data collection: VB, IAE, MvdB, DJS, PMH. Project supervi-

sion: SDP. Manuscript preparation: SDP. Manuscript revision: FSB, VB, IAE, PMH, DJS, MvdB, AF, SDP.

Conflict of Interest

None declared.

Declaration of Artificial Intelligence Involvement

No artificial intelligence was used for this study, nor for the writing of the manuscript.

References

1. Burgoyne RA, Fisher AJ, Borthwick LA. The role of epithelial damage in the pulmonary immune response. *Cells*. 2021;10:2763.
2. Pouwels SD, Heijink IH, ten Hacken NHT, Vandenaabeele P, Krysko DV, Nawijn MC, et al. DAMPs activating innate and adaptive immune responses in COPD. *Mucosal Immunol*. 2014;7:215–26.
3. Ferhani N, Letuve S, Kozhich A, Thibaudeau O, Grandsaigne M, Maret M, et al. Expression of high-mobility group box 1 and of receptor for advanced glycation end products in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2010;181:917–27.
4. Kanazawa H, Tochino Y, Asai K, Ichimaru Y, Watanabe T, Hirata K. Validity of HMGB1 measurement in epithelial lining fluid in patients with COPD. *Eur J Clin Invest*. 2012;42:419–26.
5. Huang X, Tan X, Liang Y, Hou C, Qu D, Li M, et al. Differential DAMP release was observed in the sputum of COPD, asthma and asthma-COPD overlap (ACO) patients. *Sci Rep*. 2019;9:19241.
6. Ko H-K, Hsu W-H, Hsieh C-C, Lien T-C, Lee T-S, Kou YR. High expression of high-mobility group box 1 in the blood and lungs is associated with the development of chronic obstructive pulmonary disease in smokers. *Respirology*. 2014;19:253–61.
7. Pouwels SD, van Geffen WH, Jonker MR, Kerstjens HAM, Nawijn MC, Heijink IH. Increased neutrophil expression of pattern recognition receptors during COPD exacerbations. *Respirology*. 2017;22:401–4.
8. Brajer-Luftmann B, Nowicka A, Kaczmarek M, Wyrzykiewicz M, Yasar S, Piorunek T, et al. Molecules of damage-associated patterns in bronchoalveolar lavage fluid and serum in chronic obstructive pulmonary disease. *Adv Exp Med Biol*. 2019;1113:27–35.
9. Faiz A, Heijink IH, Vermeulen CJ, Guryev V, van den Berge M, Nawijn MC, et al. Cigarette smoke exposure decreases CFLAR expression in the bronchial epithelium, augmenting susceptibility for lung epithelial cell death and DAMP release. *Sci Rep*. 2018;8:12426.
10. Heijink IH, Pouwels SD, Leijendekker C, de Bruin HG, Zijlstra GJ, van der Vaart H, et al. Cigarette smoke-induced damage-associated molecular pattern release from necrotic neutrophils triggers proinflammatory mediator release. *Am J Respir Cell Mol Biol*. 2015;52:554–62.
11. Pouwels SD, Faiz A, den Boef LE, Gras R, van den Berge M, Boezen HM, et al. Genetic variance is associated with susceptibility for cigarette smoke-induced DAMP release in mice. *Am J Physiol Lung Cell Mol Physiol*. 2017;313:L559–80.
12. Pouwels SD, Hesse L, Faiz A, Lubbers J, Bodha PK, Ten Hacken NHT, et al. Susceptibility for cigarette smoke-induced DAMP release and DAMP-induced inflammation in COPD. *Am J Physiol Lung Cell Mol Physiol*. 2016;311:L881–92.
13. Pouwels SD, Heijink IH, van Oosterhout AJM, Nawijn MC. A specific DAMP profile identifies susceptibility to smoke-induced airway inflammation. *Eur Respir J*. 2014;43:1183–6.
14. Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X. Rare-variant association testing for sequencing data with the sequence kernel association test. *Am J Hum Genet*. 2011;89:82–93.
15. Zhong Y, Jiang L, Lin H, Li X, Long X, Zhou Y, et al. Overexpression of *KIF18A* promotes cell proliferation, inhibits apoptosis, and independently predicts unfavorable prognosis in lung adenocarcinoma. *IUBMB Life*. 2019;71:942–55.
16. Tajbakhsh A, Gheibihayat SM, Mortazavi D, Medhati P, Rostami B, Savardash-taki A, et al. The effect of cigarette smoke exposure on efferocytosis in chronic obstructive pulmonary disease; molecular mechanisms and treatment opportunities. *COPD*. 2021;18:723–36.
17. Lu Z, Van Eckhoutte HP, Liu G, Nair PM, Jones B, Gillis CM, et al. Necroptosis signaling promotes inflammation airway remodeling, and emphysema in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med*. 2021;204:667–81.
18. Yang W, Lu S, Peng L, Zhang Z, Zhang Y, Guo D, et al. Integrated analysis of necroptosis-related genes for evaluating immune infiltration and colon cancer prognosis. *Front Immunol*. 2022;13:1085038.
19. Pouwels SD, Zijlstra GJ, van der Toorn M, Hesse L, Gras R, Ten Hacken NHT, et al. Cigarette smoke-induced necroptosis and DAMP release trigger neutrophilic airway inflammation in mice. *Am J Physiol Lung Cell Mol Physiol*. 2016;310:L377–86.

Fia Sabrina Boedijono^{a,b}, Verena Bood^{c,d,e},
Ilse A. Eichhorn^{c,d,e}, Philip M. Hansbro^b,
Dirk-Jan Slebos^{c,e}, Maarten van den Berge^{c,e}, Alen Faiz^{a,1},
Simon D. Pouwels^{c,d,e,*}

^a Respiratory Bioinformatics and Molecular Biology Group, University of Technology Sydney, Australia

^b Centre for Inflammation, Centenary Institute and University of Technology Sydney, Faculty of Science, School of Life Sciences, Sydney, Australia

^c Department of Pulmonary Diseases, University Medical Center Groningen, The Netherlands

^d Department of Pathology and Medical Biology, University Medical Center Groningen, Groningen, The Netherlands

^e GRIAC Research Institute, University of Groningen, Groningen, The Netherlands

* Corresponding author.

E-mail address: s.d.pouwels@umcg.nl (S.D. Pouwels).

✉ [@pouwelscience](https://twitter.com/pouwelscience) (S.D. Pouwels)

¹ These authors contributed equally.